| State: | New Jersey |
|---|---|
| Address: | 100 Bayer Blvd, Whippany, NJ 07981 |
| Zip code: | 07981 |
| Phone: | (888) 842-2937 |
| Website: | https://www.stivarga-us.com/contact-us/ |
Stivarga is located in Morris County of New Jersey state. On the street of Bayer Boulevard and street number is 100. To communicate or ask something with the place, the Phone number is (888) 842-2937. You can get more information from their website.
The coordinates that you can use in navigation applications to get to find Stivarga quickly are 40.8174695 ,-74.4120962
There are no reviews yet!
You can review this Business and help others by leaving a comment. If you want to share your thoughts about Stivarga, use the form below and your opinion, advice or comment will appear in this space.
Important contact information for STIVARGA® (regorafenib) product inquiries and patient support. Visit STIVARGA-US.com to see full safety and Prescribing Information, including Boxed Warning. ... Contact Us. For help with questions about STIVARGA. Bayer 100 Bayer Blvd. Whippany, NJ 07981 PHONE: 1-888-84Bayer (1-888-842-2937)
https://www.stivarga-us.com/contact-us100 Bayer Blvd. Whippany, NJ 07981. PHONE: 1-888-84Bayer (1-888-842-2937) Click here to report an adverse event. Click here if you are a US healthcare professional seeking medical information.
https://www.hcp.stivarga-us.com/contact-usSTIVARGA for a condition for which it was not prescribed. Do not give STIVARGA to other people even if they have the same symptoms you have. It may harm them. ... For more information, go to www.STIVARGA-US.com or call 1-888-842-2937. This Patient Information has been approved by the U.S. Food and Drug Administration.
https://labeling.bayerhealthcare.com/html/products/pi/Stivarga_PPI.pdfHIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use STIVARGA safely and effectively. See full prescribing information for STIVARGA. STIVARGA® (regorafenib) tablets, for oral use ... HealthCare Pharmaceuticals Inc. at 1 -888 842 2937 or FDA at 1 800
https://labeling.bayerhealthcare.com/html/products/pi/Stivarga_PI.pdfFor Important risk and use information for STIVARGA, including the Boxed Warning, please see the full Prescribing Information, ... 1-888-84Bayer (1-888-842-2937) Co-pay Program Technical Assistance: PHONE: 1-866-581-4992 . For help with questions about REACH: REACH Program PHONE: 1-866-639-2827 24 hrs a day, 365 days a year ...
https://www.zerocopaysupport.com/ContactHealthCare Pharmaceuticals Inc. at 1-888-842-2937 or FDA at 1-800 ... Stivarga caused an increased incidence of hypertension (30% versus 8% in Study 1 and 59% versus 27% in Study 2) [see Adverse Reactions (6.1)]. Hypertensive crisis occurred in 0.25% of 1200 Stivarga-treated patients across all clinical trials.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203085s004lbl.pdfStivarga® (regorafenib) www.stivarga-us.com or call 1.866.639.2827; Zaltrap® (ziv-Aflibercept) www.zaltrap.com or call 1.855.925.8727; ... Paying For Treatment During Coronavirus ... please contact Bayer at 1-888-842-2937 to determine eligibility for immediate free access to Bayer prescription medicines. If you or someone you know has ...
https://fightcolorectalcancer.org/living-with-colorectal-cancer/paying-for-treatment/HealthCare Pharmaceuticals Inc. at 1-888-842-2937 or FDA at 1-800 ... STIVARGA-treated patients compared to 8% and 3% in placebo-treated patients in Studies 1 and 2. Fatal hemorrhage occurred in 4 of 632 (0.6%) of STIVARGA-treated patients in Studies 1 and 2 and involved the respiratory,
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203085s006lbl.pdfSTIVARGA-US.com or call 1-888-842-2937. This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 4/2017. Important Contact Information | STIVARGA (regorafenib) For STIVARGA Product Inquiries: Bayer. 100 Bayer Blvd. Whippany, NJ 07981.
https://www.businessyab.com/explore/united_states/new_jersey/morris_county/hanover/whippany/bayer_boulevard/100/stivarga_99163Stivarga increased the incidence of myocardial ischemia and infarction (1.2% for Stivarga-treated patients vs. 0.4% of placebo-treated patients) [see Adverse Reactions (6.1)]. Withhold Stivarga in patients who develop new or acute onset cardiac ischemia or infarction. Resume Stivarga only after
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf